Form 8-K - Current report:
SEC Accession No. 0001731122-25-000135
Filing Date
2025-01-30
Accepted
2025-01-30 16:04:26
Documents
21
Period of Report
2025-01-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K e6318_8k.htm   iXBRL 8-K 39223
2 EXHIBIT 4.1 e6318_ex4-1.htm EX-4.1 89517
3 EXHIBIT 10.1 e6318_ex10-1.htm EX-10.1 92960
4 EXHIBIT 10.2 e6318_ex10-2.htm EX-10.2 213874
5 EXHIBIT 10.3 e6318_ex10-3.htm EX-10.3 10702
6 EXHIBIT 10.4 e6318_ex10-4.htm EX-10.4 32335
7 EXHIBIT 99.1 e6318_ex99-1.htm EX-99.1 9582
8 EXHIBIT 99.2 e6318_ex99-2.htm EX-99.2 9384
9 GRAPHIC image_002.jpg GRAPHIC 6646
  Complete submission text file 0001731122-25-000135.txt   809821

Data Files

Seq Description Document Type Size
10 XBRL SCHEMA FILE vrpx-20250127.xsd EX-101.SCH 3027
11 XBRL LABEL FILE vrpx-20250127_lab.xml EX-101.LAB 34240
12 XBRL PRESENTATION FILE vrpx-20250127_pre.xml EX-101.PRE 24173
23 EXTRACTED XBRL INSTANCE DOCUMENT e6318_8k_htm.xml XML 3810
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

EIN.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 25573636
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)